1457 ET -- Bristol-Myers Squibb is one of the most mentioned companies in the ... ([email protected]) We sell different types of products and services to both investment professionals and ...

Photo: Uwe Anspach/dpa (Photo by Uwe Anspach/picture alliance via Getty Images) However, this came as good news for investors ...

Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...

Bristol-Myers Squibb Up Over 11%, on Pace for Largest Percent Increase Since March 2000 — Data Talk Bristol-Myers Squibb Company (BMY) is currently at $60.49, up $6.35 or 11.73% --Would be highest ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...

Truist analyst Srikripa Devarakonda notes that AbbVie (ABBV) announced negative trial results for emraclidine in dual Phase 2 schizophrenia ...

Try Now>> See today’s best-performing stocks on TipRanks >> Read More on BMY: Bristol-Myers Squibb NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.